SANOFI-ADR (SNY)

US80105N1054 - ADR

48.6  -0.17 (-0.35%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

SANOFI-ADR

NASDAQ:SNY (2/26/2024, 9:42:50 AM)

48.6

-0.17 (-0.35%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap121.63B
Shares
PE10.97
Fwd PE11.19
Dividend Yield4.01%
Analysts
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

SNY Daily chart

Company Profile

Sanofi engages in the research, production, and distribution of pharmaceutical products. The company is headquartered in Paris, Ile-De-France and currently employs 91,573 full-time employees. The company went IPO on 2002-07-01. The firm focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme, among others.

Company Info

SANOFI-ADR

46 Avenue de la Grande Armee

Paris ILE-DE-FRANCE 75008

P: 33153774000

CEO: Paul Hudson

Employees: 91573

Website: https://www.sanofi.com/

SNY News

News Image3 days ago - Seeking AlphaSanofi, Regeneron win FDA priority review for Dupixent label expansion (NASDAQ:SNY)

Sanofi and Regeneron's Dupixent receives priority review from FDA for its use in treating chronic obstructive pulmonary disease (COPD).

News Image4 days ago - InvestorPlaceMove Over Magnificent 7, Say Hello to the GRANOLAS

Dive into the compelling world of GRANOLAS stocks: Europe's elite players shaping the future of pharmaceuticals, tech, and consumer goods.

News Image5 days ago - Seeking AlphaRegeneron, Vertex Pharma in $100B biotech club (NASDAQ:REGN)

Regeneron (REGN) and Vertex Pharmaceuticals (VRTX) join the $100B market cap club in the biotech industry, outperforming their rivals last year. Read more here.

News Image6 days ago - Investor's Business DailyRapt Therapeutics Crashes 65% After Unexpected Liver Failure Sidelines Two Tests

The FDA put studies in eczema and asthma treatment on clinical hold.

News Image6 days ago - Seeking AlphaSanofi gains amid report of PE intersest in $20B consumer health unit

Sanofi's ADRs surge 3% as several prominent private equity firms express interest in its consumer health unit, per Bloomberg report.

News Image6 days ago - Seeking AlphaSanofi gains amid report of PE interest in $20B consumer health unit

Sanofi ADRs surge 3% as several prominent private equity firms express interest in its consumer health unit, per Bloomberg report.

SNY Twits

Here you can normally see the latest stock twits on SNY, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example